HAZLET, N.J. - May 11, 2026 - PRLog -- This symposium will emphasize prompt recognition of the disease, identifying cardiac and extracardiac clinical clues. The diagnostic algorithm will be explained and clinical evidence with current disease-modifying therapies (which act by either reducing production of new amyloid by suppressing hepatic synthesis of transthyretin (TTR) or by stabilizing the TTR protein) summarized. Supportive care with prudent use and potential adjustments of GDMT for HF will be indicated, and recommendations for monitoring of ATTR-CM disease progression identified to optimize patient outcomes.
Click here for more information
CHAIR
Margaret Cuomo, NP
Columbia University Irving Medical Center
New York, New York
FACULTY
Justin Grodin, MD, MPH
Associate Professor of Medicine
Department of Internal Medicine – Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, Texas
Educational Objectives
- Indicate red flags which raise suspicion for ATTR-CM and identify specific patient populations where the disease is prevalent
- Recognize the criteria for diagnosing ATTR-CM and interpret the evidence with disease-modifying therapies
- Discuss best use of HF GDMT in individuals with ATTR-CM
- Describe recommended monitoring of disease progression and summarize roles for HF nurses in overall management of ATTR-CM
Target Audience
This educational activity is intended for Heart Failure Nurses.
Educational Grant
This program is supported by an independent educational grant provided by Alnylam.
Accreditation and Credit Designation Statements
This activity is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.
Attendees may earn continuing education credits (CEC) by attending the meeting and completing the evaluation for the Annual Meeting sessions. Disclaimer: Learners are advised that accredited status does not imply endorsement by the provider, additional provider, or ANCC of any commercial products displayed in conjunction with an activity. Accreditation Provider Number: ANCC Provider Number: P0398.
Photos: (Click photo to enlarge)
Source: CMEPlanet
Read Full Story - 2026 AAHFN CME Symposium - Practical Management of Transthyretin Cardiac Amyloidosis | More news from this source
Press release distribution by PRLog
